10 reasons to buy
Medical Device Vigilance
become qualified today!
Device Vigilance Training course

Device Safety and Vigilance

Adverse event reporting and risk assessment for medical devices in key markets worldwide

An introduction to the principles of adverse event reporting and risk assessment as applied to medical devices in the US, Europe, and other key international markets. The US has the most developed device vigilance processes but the course also summarizes the situation in Europe, Australia, Canada and Japan too. With coverage of risk assessment, AE report types, causality and event types, this course is designed to give a solid grounding in all key aspects of vigilance within this +$300 billion sector. Updated: July 2014.

  • Average study time:
    study time

    4 hrs

  • Personal development points (CPD):
    points

    4 points

  • Price:
    points

    £79.00

Please enter the number of licences required.

Course Details

The Device Safety and Vigilance course gives you a good understanding of the basic principles of vigilance and risk analysis – the course covers the history of device vigilance & safety, key components within adverse event reporting in the clinical and post-marketing settings and an overview of signal detection & risk management.

Keeping devices on the market without interruption becomes more essential with soaring development costs. Successful navigation of adverse event reporting, trend analysis and risk assessment are keys to product longevity, consumer confidence and regulatory compliance. This module will provide you with a strong foundation of knowledge on device vigilance and safety.

Benefits for you

  • Fully compliant – This course describes the compliance requirements for the reporting of adverse events relating to medical devices. Learners also receive 4 Continual Professional Development (CPD) Points, accredited by The Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. These can be used to count towards the distance learning element of any scheme that comes under the umbrella of The Academy of Medical Royal Colleges or any other scheme for which there is mutual recognition.
  • Certified – All learners who pass the final exam receive a uniquely numbered, personal certificate to demonstrate their subject knowledge. Since the questions are picked randomly from a database, re-sitting the exam doesn’t mean taking the same questions again and again.
  • Affordable – Our cost-effective prices represent excellent value. You can easily pay up to ten-times more for face-to-face training.  We can also offer generous group discounts on larger purchases.
  • Time-saving – Our new administration system makes it incredibly quick and simple to allocate licences to multiple learners. Learners save time too by choosing when and where they complete the training. Our reporting tools make it easy for administrators to check the progress of learners and identify areas for future training.
  • Reliable and trustworthy – This course was written by Steve Jolley, a recognised expert in International drug and device vigilance. You will stay up to date with any international legislative changes in device vigilance as our training courses are constantly monitored, reviewed and updated (last updated in July 2014).  Steve Jolley is a Cambridge University graduate with 25 years’ experience in drug & device safety & vigilance, who specializes in global safety compliance, business process improvement and signal detection. He is the Chairperson of the DIA Clinical Safety and Pharmacovigilance steering committee for North America and has worked with over 80 clients in the US, Europe and Japan. He is a featured speaker with the FDA and MHRA at DIA conferences and webinars on drug safety topics including auditing and signaling.)

Course Syllabus

1. Learning objectives

2. Brief History of Device Safety & Vigilance

3. Adverse Event Reporting Terms & Definitions

What is Medical Device Reporting (MHRA perspective)?
Clinical vs. post-market ADEs - Clinical
Clinical vs. post-market ADEs - Post-marketing
FDA Requirements for MDRs
Sources of MDRs
Medical Device Report Types
Device Vigilance Definitions
MDR Reportable Events
Acronyms Used for Device Safety

4. Assessing Adverse Event Reports

The Device Vigilance Process
Assessing Device Adverse Events
Serious Adverse Event for Devices
Examples of Life Threatening Adverse Events
Intensity
Serious Vs. Severe
Causality
Causality - difficulty in establishing
Causality - classifications
Causality - definitely related
Causality - probably related
Causality - possibly related
Causality - unlikely to be related
Causality - relationship testing
Lack of Efficacy
Unanticipated ADEs
Anticipated & Unanticipated AEs

5. Global Reporting Requirements

Matrix of Global Safety Regulations
US Postmarketing Requirements for Devices
Requirements of FDA MDR Regulations
Date of Awareness
US Expedited Reporting I
US Expedited Reporting II - MDR Decision Tree
US Expedited Reporting III - Summary matrix
US Expedited Reporting IV - Malfunction Reporting
US Expedited Reporting V - Clinical trials
US Expedited Reporting VI - Alternative Summary Reporting
European Expedited Reporting I
European Expedited Reporting II - EC Criteria for Reporting 
European Expedited Reporting III - Indirect Harm
European Expedited Reporting IV - post-marketing
European Expedited Reporting V - Clinical Trials
Canadian Expedited Reporting
Australian Expedited Reporting
Japanese Expedited Reporting

6. Complaints

Definition of complaints
Complaint Files – Procedure
Customer Complaint Flowchart - MDR, CAPA
Complaint Files - MDR
MDR I - Reporting Requirements
MDR II - 5-Day Report
Non-MDR Complaints

7. Trend Analysis & Risk Management

Trend Analysis
Device Safety & Risk Assessment
US FDA National Medical Device Curriculum
Risk Assessment
Class of Device - US
Device Class I
Device Class II
Device Class III
Class of Device - Non-US
Risk Management
Sample Trend Analysis I
Sample Trend Analysis II - by Device Problem
Sample Trend Analysis II - by Event Type
Sample Trend Analysis II - by Remedial Action

 

Novartis logo                        NHS logo                        Takeda logo                        Roche logo                        DHL logo                        Baxter logo                        Quintiles logo                        King's College logo                        US AID logo                        Novo Nordisk logo                           Grunenthal logo                           Wellcome logo                           Ipsen logo                           BTG logo                           
  • 21,183 STUDENTS
  • 9,400 COMPANIES
  • 40 COUNTRIES
  • AND COUNTING.....